| Autor: |
Karna, Ranju R.1, Noerpel, Matt1, Betts, Aaron R.1,2, Scheckel, Kirk G.3 Scheckel.Kirk@epa.gov |
| Předmět: |
|
| Zdroj: |
Journal of Environmental Quality. Nov/Dec2017, Vol. 46 Issue 6, p1225-1235. 11p. |
| Abstrakt: |
Bioavailability research of soil metals has advanced considerably from default values to validated in vitro bioaccessibility (IVBA) assays for site-specific risk assessment. Previously, USEPA determined that the soil-size fraction representative of dermal adherence and consequent soil ingestion was <250 μm. This size fraction was widely used in testing efforts for both in vivo and in vitro experiments. However, recent studies indicate the <150-μm size fraction better represents the particle size that adheres to skin for potential ingestion. At issue is the relevance of validated in vivo and in vitro methods developed with <250 μm moving to the <150-μm fraction. The objectives of this study were to investigate <250-μm versus <150-μm particle size and particle size groups for evaluating lead (Pb) and arsenic (As) IVBA and speciation. Soils with different properties were homogenized, oven dried, and sieved: <250 to > 150, <150 to >75, <75 to >38, and <38 μm. Sieved versus ground subsamples of <250-μm and <150-μm bulk soils were also used for IVBA and synchrotron-based Pb and As speciation. Although we observed an increase in total and IVBA-extractable Pb and As with decreased soil particle size, changes in %IVBA of Pb and As (dependent on the ratio extractable:total) remained consistent in all of the tested soils. No significant changes in Pb and As speciation were observed across the soil fractions. The results suggest that using the more relevant <150-μm fraction will not undermine currently validated IVBA protocols in future bioavailability studies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
GreenFILE |
| Externí odkaz: |
|
Plný text